openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS When previous exposure to Halothane was followed by unexplained jaundice, consideration should be given to the use of other agents. Halothane, USP should be used in vaporizers that permit a reasonable approximation of output, and preferably of the calibrated type. The vaporizer should be placed out of circuit in closed circuit rebreathing systems; otherwise overdosage is difficult to avoid. The patient should be closely observed for signs of overdosage, i.e., depression of blood pressure, pulse rate and ventilation, particularly during assisted or controlled ventilation. Usage in Pregnancy. Safe use of Halothane has not been established with respect to possible adverse effects upon fetal development. Therefore, Halothane should not be used in women where pregnancy is possible and particularly during early pregnancy, unless, in the judgment of the physician, the potential benefits outweigh the unknown hazards to the fetus.
ADVERSE REACTIONS The following adverse reactions have been reported: Hepatic necrosis, cardiac arrest, hypotension, respiratory arrest, cardiac arrhythmias, hyperpyrexia, shivering, nausea and emesis.